Article

Navigating the commercialization of cell and gene therapies

This article was originally published on European Pharmaceutical Review (EPR) on May 19, 2025

Kevin Chinn, VP and Head of Cell and Gene Service Line at Cencora, talks about the hurdles to making cell and gene therapy a commercial success – and how to leap over them.

Read the article to explore the potential and major obstacles impacting cell and gene therapies in the pharmaceutical industry.

Pardot Form

Connect with our cell and gene experts

Schedule some time with our cell and gene experts today. We look forward to hearing from you.

Related resources

Webinar

Preparing for 2026 health policy changes and their impact on pricing, affordability, and access

Webinar

The evolving anti-obesity medication market: Payer trends, policy shifts, and access strategies

Article

Mitigating regulatory risk with holistic CMC strategies